# PLATPARP (NCT04288687)

> A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects

No report yet. It can be ordered.

- Drugs tested: niraparib
- Indication: platinum-sensitive castration-resistant prostate cancer with DNA repair defects

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04288687
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Abramson Cancer Center at Penn Medicine
- Conditions: Prostate Adenocarcinoma
- Interventions: Niraparib Pill
- Enrollment: 11
- Primary outcome: 6-Month Radiographic Progression-Free Survival (rPFS6)

## Indexed commentary on PLATPARP so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=platparp-nct04288687